Biweekly administration of cisplatin/gemcitabine in advanced nonsmall cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 5, 2005, Pages 501-507

  López Vivanco, Guillermo ^a   Viteri, Ainhoa ^a   Barceló, Ramón ^a   Muñoz, Alberto ^a   Rubio, Itziar ^a   Mañé, Joan Manel ^a   Fuente, Natalia ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

Cisplatin; Gemcitabine; Nonsmall cell lung cancer (NSCLC); Toxicity

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAIR LOSS; HUMAN; KIDNEY DISEASE; LEG ISCHEMIA; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL ISCHEMIA; SKIN MANIFESTATION; SURVIVAL RATE; THROMBOCYTOPENIA; VASCULAR DISEASE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 26444584325     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000170583.42741.cd     Document Type: Article

References (31)

1. Gazdar AF, Minna JD. Cigarettes, sex and lung adenocarcinoma. J Natl Cancer Inst. 1997;89:1563.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533-543.
3. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trials. J Clin Oncol. 1988;6:633-641.
4. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol. 1997;15:2996-3018.
5. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311:899-909.
6. American Society of Clinical Oncology. Treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-353.
7. Rosell R, Tonato M, Sandler A. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. Semin Oncol. 1998;25(suppl 9):27-34.
8. Soto Parra H, Cavina R, Latteri F, et al. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol. 2002;13:1080-1086.
9. Rothenberg ML, Sharma A, Weiss GR, et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol. 1998;9:733-738.
10. Colomer R, Llombart A, Lluch A, et al. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin Oncol. 2000;27(suppl 2):20-24.
11. Isla D, Rosell R, Sanchez JJ, et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2001;19:1071-1077.
12. Castellano D, Hitt R, Ciruelos E, et al. Biweekly vinorelbine plus gemcitabine: a phase I dose-finding study in patients with advanced solid tumors. Ann Oncol. 2003;14:783-787.
13. Denes AE, Needles BM, Schmidt A, et al. A comparison of two schedules of docetaxel in combination with gemcitabine given every other week. Proc Am Soc Clin Oncol. 2000; 19:abstract 828.
14. Rigas JR, Rothenberg ML, Davis TH, et al. Phase I clinical pharmacokinetic study of docetaxel with two gemcitabine infusion schedules. Proc Am Soc Clin Oncol. 1999;18:abstract 870.
15. López-Vivanco G, Fuente N, Barceló R, et al. A novel biweekly schedule with cisplatin and gemcitabine in advanced non-small cell lung cancer. Int J Clin Pharm Res. 2003;XXIII:9-16.
16. Hryniuk W. The importance of dose intensity in outcome of chemother-apy. In: Hellman S, De Vita V, Rosenberg S, eds. Important Advances in Oncology. Philadelphia: Lippincott; 1988:121-141.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
18. Cardenal F, López-Cabrerizo MP, Antón A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide- cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 1999;17:1-7.
19. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 2000;18:122-130.
20. Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999;17:3522-3530.
21. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
22. Zatloukal P, Petruzelka L, Zemanová M, et al. Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIB and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. 2003;41:321-331.
23. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol. 2003;21:3909-3917.
24. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol. 2003;21:3207-3213.
25. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20:4285-4291.
26. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:3025-3034.
27. Comella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 2000;18:1451-1457.
28. Le Chevalier T, Brown A, Natale R, et al. Gemcitabine in the treatment of non-small-cell lung cancer (NSCLC): a meta-analysis of survival and progression free survival data. Lung Cancer. 2003;41(suppl 2): S70(abstract O-239).
29. Barceló R, López-Vivanco G, Mañé JM, et al. Distal ischemic changes related to combination chemotherapy with cisplatin and gemcitabine: description of four cases. Ann Oncol. 2000;11:1191-1194.
30. Muñoz A, Mañé JM, Rubio I, et al. Gemcitabine and vascular toxicity. Lung Cancer. 2002;37:229.
31. Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004;100:2664-2670.